Nash Clinical Study


Authors : Palmieri B, Vadala M

Volume/Issue : Volume 5 - 2020, Issue 3 - March

Google Scholar : https://goo.gl/DF9R4u

Scribd : https://bit.ly/3c6bwmM

The Non-alcoholic fatty liver disease (NAFLD) affects the 30% of worldwide population with greater incidence (60-80%) in type 2 diabetic patients and progresses to not alcoholic steatohepatitis (NASH) with subsequent severe outcome (fibrosis cirrhosis, liver cancer). Several clinical studies showed that bile acids administration at sustained dosages can improve the NAFLD syndrome counteracting it’s worsening and death risk; we thus planned to compare the benefits and side effects of oral versus intravenous treatment of UDCA on 100 overweight not-diabetic volunteers (41 males and 59 females), with strictly similar biochemical–clinical expressions of nonalcoholic fatty liver disease (NAFLD). The patients were divided in two groups: one with 50 mg / kg /daily/os and the other with 3500 mg in 500ml saline perfusion each other day (except the weekend) for a total of 24 intravenous sessions. The results in terms of tolerability, symptoms relieve, and liver enzymes improvement defined the parenteral treatment as the most effective, being the oral burden somehow troublesome with some untoward effects not appearing in the intravenous route.

CALL FOR PAPERS


Paper Submission Last Date
30 - September - 2022

Paper Review Notification
In 1-2 Days

Paper Publishing
In 2-3 Days

Video Explanation for Published paper

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe